A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2011
10/27/2011	US20110262381 Formulation for treatment of vaginal dryness
10/27/2011	US20110262378 Rifaximin Complexes
10/27/2011	US20110262374 Novel compound ramalin and use thereof
10/27/2011	US20110262373 Personalised pharmaceutical composition containing retinoic acid, for anti-aging of the skin
10/27/2011	US20110262369 Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug
10/27/2011	US20110262368 C21 thioethers as glucocorticoid receptor agonists
10/27/2011	US20110262365 Methods of diagnosing hypersensitivity to a female reproductive hormone and treating medical conditions associated with same
10/27/2011	US20110262362 Methods for treating obesity
10/27/2011	US20110262361 effective new drug target for the treatment of tuberculosis
10/27/2011	US20110262360 Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof
10/27/2011	US20110262359 Compositions comprising enzyme-cleavable prodrugs of active agents and inhibitors thereof
10/27/2011	US20110262358 Molecular marker for cancer stem cell
10/27/2011	US20110262357 Metalloporphyrin Derivatives, Nanoparticles Comprising the Same, and Use Thereof for Photodynamic Therapy
10/27/2011	US20110262356 Active Particles for Bio-Analytical Applications and Methods for Preparation Thereof
10/27/2011	US20110262355 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
10/27/2011	US20110262354 Cyanine-containing compounds for cancer imaging and treatment
10/27/2011	US20110262352 Aryl piperazine and their use as alpha2c antagonists
10/27/2011	US20110262347 Methods and compositions for enhanced delivery of compounds
10/27/2011	US20110262025 Cosmetic Compositions and Methods for Maintaining and Improving Barrier Function of the Stratum Corneum and to Reduce the Visible Signs of Aging in Skin
10/27/2011	CA2837400A1 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
10/27/2011	CA2833912A1 Aav-based treatment of cholesterol-related disorders
10/27/2011	CA2833905A1 Multicistronic expression constructs
10/27/2011	CA2831279A1 Method of treating gastric cancer
10/27/2011	CA2831208A1 Method of treating prostate cancer
10/27/2011	CA2831206A1 Method for treating pancreatic cancer
10/27/2011	CA2819408A1 Micheliolide derivatives, medicinal composition, producing method and usage thereof
10/27/2011	CA2812043A1 Pyrimidinedione anti-viral compounds
10/27/2011	CA2811989A1 Diarylpyridine anti-viral compounds
10/27/2011	CA2807374A1 Aliskiren in form of a solid dispersion
10/27/2011	CA2800470A1 Chemosensory receptor ligand-based therapies
10/27/2011	CA2800260A1 Compositions and method for the treatment of multiple myeloma
10/27/2011	CA2800122A1 Osmium (ii) arene azo and imino anti-cancer complexes
10/27/2011	CA2797098A1 Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof
10/27/2011	CA2797019A1 Modulators of 5-ht receptors and methods of use thereof
10/27/2011	CA2796978A1 A process for particle processing of active pharmaceutical ingredients
10/27/2011	CA2796964A1 Intermediates for the preparation of hmg-coa reductase inhibitors
10/27/2011	CA2796726A1 Lysine specific demethylase-1 inhibitors and their use
10/27/2011	CA2796710A1 Valsartan derivatives carrying nitrogen oxide donors for the treatment of vascular and metabolic diseases
10/27/2011	CA2796642A1 Pharmaceutical compositions and administrations thereof
10/27/2011	CA2796637A1 Certain amino-pyrimidines, compositions thereof, and methods for their use
10/27/2011	CA2796602A1 Pharmaceutical compositions and administrations thereof
10/27/2011	CA2796592A1 Compounds provided with antioxidant activity against free radicals, and pharmaceutical and cosmetic compositions containing them
10/27/2011	CA2796494A1 Pharmaceutical composition
10/27/2011	CA2795815A1 Novel structurally designed shrnas
10/27/2011	CA2795526A1 Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes as vasopressin v1a receptor antagonists
10/27/2011	CA2795521A1 A solid pharmaceutical composition for neutralizing stomach acid
10/27/2011	CA2795422A1 Pyrrolopyridine inhibitors of kinases
10/27/2011	CA2795222A1 Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof
10/27/2011	CA2794724A1 Oxazole derivatives useful as modulators of faah
10/27/2011	CA2794439A1 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment
10/27/2011	CA2794176A1 Novel benzamide derivatives
10/27/2011	CA2794127A1 Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
10/27/2011	CA2792950A1 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
10/27/2011	CA2786837A1 Pyrrazolopyridine derivatives
10/27/2011	CA2727957A1 Pharmaceutical composition comprising levamlodipine and indapamide
10/26/2011	EP2380898A1 Process to make glucocortisoid compounds
10/26/2011	EP2380897A1 RNAi modulation of ApoB and uses thereof
10/26/2011	EP2380892A1 Imidazothiazole derivative having proline ring structure
10/26/2011	EP2380891A1 Substituted piperidino-dihydrothienopyrimidines
10/26/2011	EP2380890A1 New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors
10/26/2011	EP2380889A2 Thiazolyl MGLUR5 antagonists and methods for their use
10/26/2011	EP2380885A1 Guanidine compounds and use of same as binding partners for 5-HT5 receptors
10/26/2011	EP2380884A1 Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof
10/26/2011	EP2380881A1 Novel bicyclic heterocyclic compound
10/26/2011	EP2380879A1 Tetrahydroindolone and tetrahydroindazolone derivatives
10/26/2011	EP2380878A1 Cyclic compound having hetero atom
10/26/2011	EP2380877A1 Pyridine-3-carboxyamide derivative
10/26/2011	EP2380876A1 1-heterodiene derivative and harmful organism control agent
10/26/2011	EP2380874A2 Pleuromutilin derivatives for the treatment of diseases mediated by microbes
10/26/2011	EP2380872A1 Polycationic compounds and uses thereof
10/26/2011	EP2380657A1 Ceramide dispersion, and process for producing same
10/26/2011	EP2380632A1 The use of NMDA antagonists to attenuate vitreoretinal vascular endothelial growth factor (VEGF) protein levels in animals
10/26/2011	EP2380631A1 Heteroaryl derivatives as DGAT1 inhibitors
10/26/2011	EP2380586A2 Oligopeptides as coating material for medical products
10/26/2011	EP2380584A1 Immunostimulatory method
10/26/2011	EP2380582A1 Low-concentration nutritional composition
10/26/2011	EP2380579A1 Beneficial effects of increasing local blood flow
10/26/2011	EP2380578A1 Bioactive agent, pharmaceutical product, cosmetic product, freshness keeping agent, and plant and animal growth promoting agent
10/26/2011	EP2380576A2 Methods and related compositions for reduction of fat
10/26/2011	EP2380575A1 Eslicarbazepine acetate and methods of use
10/26/2011	EP2380574A1 Eslicarbazepine acetate and methods of use
10/26/2011	EP2380573A1 Eslicarbazepine acetate and methods of use
10/26/2011	EP2380572A1 Cancer treatment method
10/26/2011	EP2380571A1 Biosynthesis of derivatives of monacolin j
10/26/2011	EP2380570A1 Pharmaceutical composition for preventing and treating diabetic nephropathy and preparation method thereof
10/26/2011	EP2380569A2 Osmolyte for treating allergic or viral airway illnesses
10/26/2011	EP2380568A1 Method of producing and crystallizing reduced coenzyme Q10
10/26/2011	EP2380567A1 Melanin production inhibitor
10/26/2011	EP2380566A2 Treatment of insulin resistance or diseases associated with insulin resistance using steviol or isosteviol
10/26/2011	EP2380565A1 Compositions for dental treatment comprising Lipoteichoic acids or parts thereof like mono- or polyglycerphosphates
10/26/2011	EP2380563A1 A enteric formulation of duloxetine and its core and prepration method
10/26/2011	EP2380562A1 A controlled-released osmotic pump tablet with lubricating layer and the preparation thereof
10/26/2011	EP2380561A1 Extended release formulation comprising indapamide
10/26/2011	EP2380560A1 Matrix tablets containing pramipexol
10/26/2011	EP2380023A2 Oxidized cardiolipin as a novel pro-inflammatory factor
10/26/2011	EP2379579A1 Hcv ns3 protease inhibitors
10/26/2011	EP2379576A1 HYDROSOLUBLE [6)-O-alpha-D-GLCP-(1->]n-6-O-beta-D-GLCP-(1->-PHENOLIC DERIVATIVES WITH DERMOCOSMETIC, NUTRITIONAL AND THERAPEUTIC APPLICATIONS, AND COMPOSITIONS CONTAINING SAID WATER SOLUBLE COMPOUNDS
10/26/2011	EP2379566A2 Gamma secretase modulators
10/26/2011	EP2379565A1 Piperidine and piperazine derivatives and methods of use thereof
10/26/2011	EP2379564A1 Bicyclic heterocyclic derivatives and methods of use thereof

1 ... 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 ... 7860